Tempus AI has announced it is acquiring Personalis, an oncology testing company.
The acquisition value is reported as $1.5 billion.
$1.5 billion
Acquisition price for Personalis by Tempus AI
According to reports, Tempus AI shares fell after the acquisition announcement.
The acquisition is expected to drive growth in minimal residual disease (MRD) testing, as per one source.
Needham cut its rating on Personalis stock in relation to the Tempus AI acquisition, according to a source.
A separate source reports that Needham reiterated its rating on Tempus AI stock following the deal.
Another source states that Tempus AI stock maintains a Buy rating after the acquisition.
